Alzheimer Disease
📧 Sign up to get email alerts when something new happens for Alzheimer Disease.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-07-17EMA Authorised: Nimvastid (rivastigmine) — Krka, d.d., Novo mesto
EMA authorised Nimvastid (rivastigmine) by Krka for treatment of dementia, including Alzheimer's disease and Parkinson's disease.
-
FDA approval · 2025-07-15FDA Approved: MEMANTINE AND DONEPEZIL — Original Application (Macleods Pharmaceuticals Limited)
FDA approved an original application for a generic memantine and donepezil combination from Macleods Pharmaceuticals Limited.
-
FDA approval · 2025-07-15FDA Approved: MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE — Original Application (Vitruvias Therapeutics, Inc.)
FDA approved a fixed-dose combination of memantine hydrochloride and donepezil hydrochloride as an original application by Vitruvias Therape…
-
FDA approval · 2025-07-01FDA Approved: KISUNLA — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for Kisunla (donanemab-azbt) from Eli Lilly and Company.
-
FDA approval · 2025-06-23FDA Approved: AMYVID — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for AMYVID (florbetapir F-18) submitted by Eli Lilly and Company. The action relates to the imag…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-06-23FDA Approved: VIZAMYL — Supplemental Application (GE Healthcare Inc. (Medi-Physics, Inc. dba GE Healthcare))
FDA approved a supplemental application for VIZAMYL (flutemetamol F-18) from GE Healthcare.
-
FDA approval · 2025-06-23FDA Approved: NEURACEQ — Supplemental Application (Lantheus Biosciences Ltd.)
FDA approved a supplemental application for NEURACEQ (Florbetaben F 18) submitted by Lantheus Biosciences Ltd.
-
EMA approval · 2025-06-20EMA Authorised: Memantine Merz (memantine hydrochloride) — Merz Pharmaceuticals GmbH
EMA authorised Memantine Merz (memantine hydrochloride) for Alzheimer’s disease.
-
EMA approval · 2025-06-20EMA Authorised: Axura (memantine hydrochloride) — Merz Pharmaceuticals GmbH
EMA authorised Axura (memantine hydrochloride) by Merz Pharmaceuticals GmbH for the treatment of Alzheimer disease. This marks EU marketing …
-
FDA approval · 2025-06-16FDA Approved: RIVASTIGMINE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA has approved a supplemental application for rivastigmine from Zydus Pharmaceuticals USA Inc., indicating an approved change to the gener…
-
EMA approval · 2025-06-13EMA Authorised: Rivastigmine Actavis (rivastigmine hydrogen tartrate) — Actavis Group PTC ehf
EMA authorised Rivastigmine Actavis (rivastigmine hydrogen tartrate) for dementia-related indications including Alzheimer's disease and Park…
-
FDA approval · 2025-06-10FDA Approved: VIZAMYL — Supplemental Application (GE Healthcare Inc. (Medi-Physics, Inc. dba GE Healthcare))
FDA approved a supplemental application for Vizamyl (flutemetamol F-18) by GE Healthcare, authorizing changes to the product’s labeling.
-
FDA approval · 2025-04-25FDA Approved: MEMANTINE HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for memantine hydrochloride (generic) by Amneal Pharmaceuticals LLC.
-
FDA approval · 2025-04-18FDA Approved: MEMANTINE HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for memantine hydrochloride (generic memantine) from Rising Pharma Holdings, Inc. This action confir…
-
EMA approval · 2025-04-15EMA Authorised: Prometax (rivastigmine) — Almirall, S.A.
The EMA authorised Prometax (rivastigmine) for the treatment of Alzheimer's disease, Parkinson's disease, and dementia. The decision date is…
-
FDA approval · 2025-04-02FDA Approved: DONEPEZIL — Supplemental Application (Quallent Pharmaceuticals Health LLC)
The FDA approved a supplemental application to market a generic donepezil hydrochloride product from Quallent Pharmaceuticals Health LLC (AN…
-
FDA approval · 2025-02-27FDA Approved: MEMANTINE AND DONEPEZIL HYDROCHLORIDES EXTENDED-RELEASE — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approved a supplemental application to market Memantine and Donepezil Hydrochlorides Extended-Release from Amneal Pharmaceuticals NY LLC…
-
FDA approval · 2025-01-24FDA Approved: LEQEMBI — Supplemental Application (Eisai Inc.)
FDA approves a supplemental application for LEQEMBI (lecanemab) submitted by Eisai Inc., resulting in labeling changes.
-
FDA approval · 2025-01-22FDA Approved: RIVASTIGMINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for rivastigmine by Mylan Pharmaceuticals Inc. The approval indicates a modification to the product'…
-
FDA approval · 2025-01-22FDA Approved: RIVASTIGMINE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for rivastigmine from Amneal Pharmaceuticals LLC.
-
EMA approval · 2024-11-15Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2024
The CHMP recommended Leqembi (lecanemab) for the treatment of early Alzheimer's disease, indicating EMA support ahead of final authorization…
-
EMA approval · 2024-11-14Leqembi recommended for treatment of early Alzheimer’s disease
The EMA CHMP recommended Leqembi (lecanemab) for treatment of early Alzheimer's disease in a restricted patient population after a re-examin…
-
FDA approval · 2024-11-14FDA Approved: LEQEMBI — Supplemental Application (Eisai Inc.)
The FDA approved a supplemental application for LEQEMBI (lecanemab) submitted by Eisai Inc.
-
FDA approval · 2024-09-17FDA Approved: DONEPEZIL HYDROCHLORIDE — Supplemental Application (Solco Healthcare US, LLC)
FDA approved a supplemental application for a generic donepezil hydrochloride product by Solco Healthcare US, LLC.
-
FDA approval · 2024-07-26FDA Approved: ZUNVEYL — Original Application (Alpha Cognition, Inc.)
The FDA approved ZUNVEYL (benzgalantamine) from Alpha Cognition, Inc. via an original NDA, adding a new treatment option for Alzheimer's dis…